About Dompé
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
- Headquarter Milan, Italy
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dompe Us Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.18 M (USD), Grant
Nov 15, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Dompé
Unlock access to complete
Funding Insights of Dompé
Investors in Dompé
Dompé has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Dompé
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dompé
Investment portfolio details for Dompé
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dompé
Detailed financials for Dompé
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dompé Comparisons
Peer comparison for Dompé
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dompé
Detailed competitors of Dompé
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dompé
Complete news archive for Dompé
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dompé
Dompé was founded in 1940 and raised its 1st funding round 75 years after it was founded.
Dompé is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Dompé is focussed on the development of treatment solutions for rare and often orphan diseases in areas such as diabetes, organ transplants, ophthalmology and oncology. Its product candidates are either SMW GPCRs modulators or Biotech NCEs. Its portfolio includes Reparixin, a pancreatic islet and lung transplant in phase 3 trials; Ladarixin in phase1 trials for onset type 1 diabetes; rhNGF (recombinant human nerve growth factor) for keratitis (phase 3), retinitis pigmentosa (phase 2) and Glaucoma (phase 1) ; Reparixin in phase 2 for breast cancer and Gabapentin in phase 3 trials for pediatric pain.
Dompé has 1 investor. Key investors include European Union.